The multifunctional role of phosphodiesterase 5 inhibitors in medicine
Abstract
Phosphodiesterase type 5 inhibitors (PDE5Is), used primarily to treat erectile dysfunction and pulmonary hypertension, are gaining attention for their potential off-label applications and new prospects for their use in various fields of medicine. Their current off-label indications are widely used in cases such as cardiovascular and pulmonary diseases, and Alzheimer's disease. In oncology, PDE5Is have shown promising effects in increasing the efficacy of traditional chemotherapy. By modulating immune responses and increasing drug sensitivity, these drugs may be helpful in treating various cancers. In obstetrics and gynecology, PDE5Is are being studied for their ability to improve placental blood flow, which may have potential in treating restricted fetal growth, and in improving the ability of the endometrium to accept an embryo, which could aid in the treatment of infertility. In diabetes, PDE5Is have been shown to improve endothelial function, glucose metabolism, and vascular health, with potential benefits in treating complications such as diabetic neuropathy and erectile dysfunction. These promising applications underscore the growing interest in PDE5Is beyond their traditional indications. However, clinical evidence is still limited, with most data coming from preclinical studies and small trials. Further controlled studies are needed to better understand the safety, efficacy, and long-term outcomes of these therapies in the context of indications other than erectile…
Read the paper
Related studies
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response
- Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer
- Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health
- Long-term outcomes after treatment with Optilume BPH: Four-year results from the EVEREST study
- Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.